Show simple item record

dc.contributor.authorKaur, Jasmine
dc.contributor.authorElms, Jackson
dc.contributor.authorMunn, Alan L
dc.contributor.authorGood, David
dc.contributor.authorWei, Ming Q
dc.date.accessioned2021-07-16T01:14:06Z
dc.date.available2021-07-16T01:14:06Z
dc.date.issued2021
dc.identifier.issn1040-8428
dc.identifier.doi10.1016/j.critrevonc.2021.103417
dc.identifier.urihttp://hdl.handle.net/10072/406038
dc.description.abstractNon-small cell lung cancer (NSCLC) is of major concern for society as it is associated with high mortality and is one of the most commonly occurring of all cancers. Due to the number of mutational variants and general heterogeneity of this type of cancer, treatment using conventional modalities has been challenging. Therefore, it is important to have improved therapeutic treatments like immunotherapy, that can specifically treat the disease while causing minimal damage to healthy tissue and additionally provide systemic immunity. Cancer vaccines are an important element of cancer immunotherapy and have been approved for treatment of a limited number of cancers, including NSCLC. This article highlights scientific evidence for several therapeutic treatment strategies for NSCLC, alone or in combination, which offers new hope for those suffering. Although cancer vaccines have had some success as a monotherapy, their potential in a combination therapy needs to be critically analyzed for future applications.
dc.description.peerreviewedYes
dc.languageeng
dc.publisherElsevier BV
dc.relation.ispartofpagefrom103417
dc.relation.ispartofjournalCritical Reviews in Oncology/Hematology
dc.relation.ispartofvolume164
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.fieldofresearchCardiorespiratory Medicine and Haematology
dc.subject.fieldofresearchcode1112
dc.subject.fieldofresearchcode1102
dc.subject.keywordsCancer vaccines
dc.subject.keywordsCheckpoint inhibitors
dc.subject.keywordsCombination therapy
dc.subject.keywordsConventional treatments
dc.subject.keywordsImmunotherapy
dc.titleImmunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationKaur, J; Elms, J; Munn, AL; Good, D; Wei, MQ, Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy, Critical Reviews in Oncology/Hematology, 2021, 164, pp. 103417
dcterms.dateAccepted2021-07-04
dc.date.updated2021-07-15T20:37:32Z
gro.hasfulltextNo Full Text
gro.griffith.authorElms, Jackson S.
gro.griffith.authorMunn, Alan L.
gro.griffith.authorKaur, Jasmine
gro.griffith.authorWei, Ming Q.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record